Yuan Li1,2, Liqing Lu1,3, Jian Tu1,4, Jing Zhang1,5, Ting Xiong1,3, Wei Fan1, Jiaohong Wang1, Meng Li6, Yibu Chen6, Justin Steggerda7, Hui Peng1, Yongheng Chen3, Tony W H Li1, Zhi-Gang Zhou8, José M Mato9, Ekihiro Seki1, Ting Liu2,3, Heping Yang1, Shelly C Lu1. 1. Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA. 2. Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, China. 3. Key Laboratory of Cancer proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, China. 4. Institute of Pharmacy and Pharmacology, University of South China, Hengyang, China. 5. Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 6. Libraries Bioinformatics, University of Southern California, Los Angeles, CA. 7. Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. 8. Department of Anesthesia, The First Affiliated Hospital, University of South China, Hengyang, China. 9. CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Technology, Derio, Spain.
Abstract
BACKGROUND AND AIMS: Forkhead box M1 (FOXM1) and nuclear factor kappa B (NF-ĸB) are oncogenic drivers in liver cancer that positively regulate each other. We showed that methionine adenosyltransferase 1A (MAT1A) is a tumor suppressor in the liver and inhibits NF-ĸB activity. Here, we examined the interplay between FOXM1/NF-κB and MAT1A in liver cancer. APPROACH AND RESULTS: We examined gene and protein expression, effects on promoter activities and binding of proteins to promoter regions, as well as effects of FOXM1 inhibitors T0901317 (T0) and forkhead domain inhibitory-6 (FDI-6) in vitro and in xenograft and syngeneic models of liver cancer. We found, in both hepatocellular carcinoma and cholangiocarcinoma, that an induction in FOXM1 and NF-κB expression is accompanied by a fall in MATα1 (protein encoded by MAT1A). The Cancer Genome Atlas data set confirmed the inverse correlation between FOXM1 and MAT1A. Interestingly, FOXM1 directly interacts with MATα1 and they negatively regulate each other. In contrast, FOXM1 positively regulates p50 and p65 expression through MATα1, given that the effect is lost in its absence. FOXM1, MATα1, and NF-κB all bind to the FOX binding sites in the FOXM1 and MAT1A promoters. However, binding of FOXM1 and NF-κB repressed MAT1A promoter activity, but activated the FOXM1 promoter. In contrast, binding of MATα1 repressed the FOXM1 promoter. MATα1 also binds and represses the NF-κB element in the presence of p65 or p50. Inhibiting FOXM1 with either T0 or FDI-6 inhibited liver cancer cell growth in vitro and in vivo. However, inhibiting FOXM1 had minimal effects in liver cancer cells that do not express MAT1A. CONCLUSIONS: We have found a crosstalk between FOXM1/NF-κB and MAT1A. Up-regulation in FOXM1 lowers MAT1A, but raises NF-κB, expression, and this is a feed-forward loop that enhances tumorigenesis.
BACKGROUND AND AIMS: Forkhead box M1 (FOXM1) and nuclear factor kappa B (NF-ĸB) are oncogenic drivers in liver cancer that positively regulate each other. We showed that methionine adenosyltransferase 1A (MAT1A) is a tumor suppressor in the liver and inhibits NF-ĸB activity. Here, we examined the interplay between FOXM1/NF-κB and MAT1A in liver cancer. APPROACH AND RESULTS: We examined gene and protein expression, effects on promoter activities and binding of proteins to promoter regions, as well as effects of FOXM1 inhibitors T0901317 (T0) and forkhead domain inhibitory-6 (FDI-6) in vitro and in xenograft and syngeneic models of liver cancer. We found, in both hepatocellular carcinoma and cholangiocarcinoma, that an induction in FOXM1 and NF-κB expression is accompanied by a fall in MATα1 (protein encoded by MAT1A). The Cancer Genome Atlas data set confirmed the inverse correlation between FOXM1 and MAT1A. Interestingly, FOXM1 directly interacts with MATα1 and they negatively regulate each other. In contrast, FOXM1 positively regulates p50 and p65 expression through MATα1, given that the effect is lost in its absence. FOXM1, MATα1, and NF-κB all bind to the FOX binding sites in the FOXM1 and MAT1A promoters. However, binding of FOXM1 and NF-κB repressed MAT1A promoter activity, but activated the FOXM1 promoter. In contrast, binding of MATα1 repressed the FOXM1 promoter. MATα1 also binds and represses the NF-κB element in the presence of p65 or p50. Inhibiting FOXM1 with either T0 or FDI-6 inhibited liver cancer cell growth in vitro and in vivo. However, inhibiting FOXM1 had minimal effects in liver cancer cells that do not express MAT1A. CONCLUSIONS: We have found a crosstalk between FOXM1/NF-κB and MAT1A. Up-regulation in FOXM1 lowers MAT1A, but raises NF-κB, expression, and this is a feed-forward loop that enhances tumorigenesis.
Authors: Bo Zhao; Luis A Barrera; Ina Ersing; Bradford Willox; Stefanie C S Schmidt; Hannah Greenfeld; Hufeng Zhou; Sarah B Mollo; Tommy T Shi; Kaoru Takasaki; Sizun Jiang; Ellen Cahir-McFarland; Manolis Kellis; Martha L Bulyk; Elliott Kieff; Benjamin E Gewurz Journal: Cell Rep Date: 2014-08-21 Impact factor: 9.423
Authors: Nuria Martínez-López; Marta Varela-Rey; David Fernández-Ramos; Ashwin Woodhoo; Mercedes Vázquez-Chantada; Nieves Embade; Luis Espinosa-Hevia; Francisco Javier Bustamante; Luis A Parada; Manuel S Rodriguez; Shelly C Lu; José M Mato; Maria L Martínez-Chantar Journal: Hepatology Date: 2010-11 Impact factor: 17.425
Authors: Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh Journal: Nat Med Date: 2015-07-20 Impact factor: 53.440
Authors: C Hu; D Liu; Y Zhang; G Lou; G Huang; B Chen; X Shen; M Gao; W Gong; P Zhou; S Dai; Y Zeng; F He Journal: Oncogene Date: 2013-07-01 Impact factor: 9.867
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Komal Ramani; Aaron E Robinson; Joshua Berlind; Wei Fan; Aushinie Abeynayake; Aleksandra Binek; Lucía Barbier-Torres; Mazen Noureddin; Nicholas N Nissen; Zehra Yildirim; Ebru Erbay; José M Mato; Jennifer E Van Eyk; Shelly C Lu Journal: Hepatology Date: 2021-12-18 Impact factor: 17.425